Media stories about DexCom (NASDAQ:DXCM) have trended somewhat positive on Sunday, according to Accern Sentiment. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. DexCom earned a media sentiment score of 0.20 on Accern’s scale. Accern also assigned media stories about the medical device company an impact score of 46.1607740416658 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment’s rankings:
- DexCom (DXCM) Downgraded by ValuEngine to “Sell” (americanbankingnews.com)
- DexCom (DXCM) Upgraded at Zacks Investment Research (americanbankingnews.com)
- DexCom (DXCM) versus Intersect ENT (XENT) Critical Comparison (americanbankingnews.com)
- Today’s Hot Mover – DexCom Inc (NASDAQ: DXCM) – Alpha Beta Stock (alphabetastock.com)
- Dexcom: Breaking A Paradigm – Seeking Alpha (seekingalpha.com)
A number of brokerages have weighed in on DXCM. Northland Securities reiterated a “sell” rating and set a $40.00 price target on shares of DexCom in a research report on Tuesday, January 16th. ValuEngine cut shares of DexCom from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Friday. Oppenheimer set a $67.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Monday, February 12th. Finally, BidaskClub lowered shares of DexCom from a “strong-buy” rating to a “buy” rating in a research note on Friday, December 22nd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $65.97.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Tuesday, February 27th. The medical device company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.07. DexCom had a negative net margin of 6.99% and a negative return on equity of 13.99%. The company had revenue of $221.00 million during the quarter, compared to the consensus estimate of $217.82 million. analysts predict that DexCom will post -0.56 EPS for the current year.
In related news, Chairman Terrance H. Gregg sold 10,000 shares of DexCom stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $55.91, for a total value of $559,100.00. Following the completion of the transaction, the chairman now owns 484,559 shares in the company, valued at $27,091,693.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Richard Doubleday sold 1,635 shares of DexCom stock in a transaction that occurred on Tuesday, December 26th. The stock was sold at an average price of $56.39, for a total transaction of $92,197.65. Following the completion of the transaction, the executive vice president now owns 65,049 shares of the company’s stock, valued at approximately $3,668,113.11. The disclosure for this sale can be found here. Insiders sold 24,908 shares of company stock valued at $1,401,535 in the last quarter. 1.70% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “DexCom (DXCM) Getting Somewhat Favorable News Coverage, Study Finds” was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/03/19/dexcom-dxcm-getting-somewhat-favorable-news-coverage-study-finds.html.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.